<?xml version = '1.0' encoding = 'UTF-8'?>
<?xml-stylesheet href="/rss/styledrssBMC.css" type="text/css"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:extra="http://www.biomedcentral.com/xml/schemas/extra/" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" xmlns:cc="http://web.resource.org/cc/">
	<channel rdf:about="http://www.biomedcentral.com/rss">
		<extra:info rdf:parseType="Literal">
			<html:div xmlns:html="http://www.w3.org/1999/xhtml" style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif">
				<html:span style="font-weight:bold">This is an RSS newsfeed from BioMed Central</html:span>
				<html:br/>
				<html:span style="font-size: 12px;">It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit <html:br/><html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">http://www.biomedcentral.com/info/about/rss/</html:a><html:br/>
				</html:span>
			</html:div>
		</extra:info>
		<title>Respiratory Research - Latest articles</title>
		<link>http://respiratory-research.com</link>
		<description>The latest articles from Respiratory Research (ISSN 1465-9921) published by 
				
				BioMed Central
		</description>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        <items>
            <rdf:Seq>
            
				    <rdf:li rdf:resource="http://respiratory-research.com/content/9/1/74"/>			    
            
				    <rdf:li rdf:resource="http://respiratory-research.com/content/9/1/73"/>			    
            
				    <rdf:li rdf:resource="http://respiratory-research.com/content/9/1/72"/>			    
            
				    <rdf:li rdf:resource="http://respiratory-research.com/content/9/1/71"/>			    
            
				    <rdf:li rdf:resource="http://respiratory-research.com/content/9/1/70"/>			    
            
				    <rdf:li rdf:resource="http://respiratory-research.com/content/9/1/69"/>			    
            
				    <rdf:li rdf:resource="http://respiratory-research.com/content/9/1/68"/>			    
            
				    <rdf:li rdf:resource="http://respiratory-research.com/content/9/1/67"/>			    
            
				    <rdf:li rdf:resource="http://respiratory-research.com/content/9/1/66"/>			    
            
				    <rdf:li rdf:resource="http://respiratory-research.com/content/9/1/65"/>			    
            
				    <rdf:li rdf:resource="http://respiratory-research.com/content/9/1/64"/>			    
            
            </rdf:Seq>
        </items>
    </channel>  
    
		<item rdf:about="http://respiratory-research.com/content/9/1/74">
            
            <title>Traffic-related air pollution and respiratory symptoms among asthmatic children, resident in Mexico City: The EVA cohort study</title>
			<description>Background:
Taffic-related air pollution has been related to adverse respiratory outcomes; however, there is still uncertainty concerning the type of vehicle emission causing most deleterious effects. Methods: A panel study was conducted among 147 asthmatic and 50 healthy children, who were followed up for an average of 22 weeks. Incidence density of coughing, wheezing and breathing difficulty was assessed by referring to daily records of symptoms and child's medication. The association between exposure to pollutants and occurrence of symptoms was evaluated using mixed-effect models with binary response and poisson regression. Results: Wheezing was found to relate significantly to air pollutants:  an increase of 17.4 ug/m3 (IQR) of PM2.5 (24-h average) was associated with an 8.8% increase (95% CI: 2.4% to 15.5%); an increase of 34 ppb (IQR) of NO2  (1-h maximum) was associated with an 9.1% increase (95% CI: 2.3% to16.4%) and  an increase of 48 ppb (IQR) in O3 levels (1 hr maximum) to an increase of. 10% (95% CI: 3.2% to 17.3%).  Diesel-fueled motor vehicles were significantly associated with wheezing and bronchodilator use (IRR=1.29; 95% CI: 1.03 to 1.62, and IRR=1.32; 95% CI: 0.99 to 1.77, respectively, for an increase of 130 vehicles hourly, above the 24-hour average). Conclusions: Respiratory symptoms in asthmatic children were significantly associated with exposure to traffic exhaust, especially from natural gas and diesel-fueled vehicles.</description>
			<link>http://respiratory-research.com/content/9/1/74</link>
			
			 	<dc:creator>Maria-Consuelo CE Escamilla-Nunez, Albino AB Barraza-Villarreal, Leticia LH Hernandez-Cadena, Hortensia HM Moreno-Macias, Matiana MR Ramirez-Aguilar, Juan-Jose JS Sienra-Monge, Marlene MC Cortez, Jose-Luis JT Texcalac, Blanca BR Del-Rio-Navarro and Isabelle IR Romieu</dc:creator>
			
			<dc:source>Respiratory Research 2008, 9:74</dc:source>
			<dc:date>2008-11-16</dc:date>
			<dc:identifier>doi:10.1186/1465-9921-9-74</dc:identifier>
			
			
							
					<prism:publicationName>Respiratory Research</prism:publicationName>
					
			
							
					<prism:issn>1465-9921</prism:issn>
					
			
							
					<prism:volume>9</prism:volume>
					
			
							
					<prism:startingPage>74</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-11-16</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://respiratory-research.com/content/9/1/73">
            
            <title>One-Year treatment with mometasone furoate in chronic obstructive pulmonary disease</title>
			<description>Many patients with chronic obstructive pulmonary disease (COPD) are treated with twice daily (BID) inhaled corticosteroids (ICS). This study evaluated whether daily PM mometasone furoate administered via a dry powder inhaler (MF-DPI) was equally effective compared to twice daily dosing.
In a 52-week, randomized, double-blind, placebo-controlled study, 911 subjects with moderate-to-severe COPD managed without ICS received MF-DPI 800 mcg QD PM, MF-DPI 400 mcg BID, or placebo. The change from baseline in postbronchodilator forced expiratory volume in 1 second (FEV1), total COPD symptom scores, and health status as well as the percentage of subjects with a COPD exacerbation were assessed. Adverse events were recorded.
Mometasone furoate administered via a dry powder inhaler 800 mcg QD PM and 400 mcg BID significantly increased postbronchodilator FEV1 from baseline (50 mL and 53 mL, respectively, versus a 19-mL decrease for placebo; P&lt;0.001). The percentage of subjects exacerbating was significantly lower in the pooled MF-DPI groups than in the placebo group (P=0.043). Subjects receiving MF-DPI 400 mcg BID reported a statistically significant (19%) reduction in COPD symptom scores compared with placebo (P&lt;0.001). Health status as measured with St. George's Respiratory Questionnaire (SGRQ) improved significantly in all domains (Total, Activity, Impacts, and Symptoms) in the pooled MF-DPI groups versus placebo (P[less than or equal to]0.031). MF-DPI treatment was well tolerated. 
Once-daily MF-DPI improved lung function and health status in subjects with moderate-to-severe COPD and was comparable to BID MF-DPI.</description>
			<link>http://respiratory-research.com/content/9/1/73</link>
			
			 	<dc:creator>Peter MA Calverley, Stephen Rennard, Harold S Nelson, Jill P Karpel, Eduardo H Abbate, Paul Stryszak and Heribert Staudinger</dc:creator>
			
			<dc:source>Respiratory Research 2008, 9:73</dc:source>
			<dc:date>2008-11-13</dc:date>
			<dc:identifier>doi:10.1186/1465-9921-9-73</dc:identifier>
			
			
							
					<prism:publicationName>Respiratory Research</prism:publicationName>
					
			
							
					<prism:issn>1465-9921</prism:issn>
					
			
							
					<prism:volume>9</prism:volume>
					
			
							
					<prism:startingPage>73</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-11-13</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://respiratory-research.com/content/9/1/72">
            
            <title>An intranasal selective antisense oligonucleotide impairs lung cyclooxygenase-2 production and improves inflammation, but worsens airway function, in house dust mite sensitive mice </title>
			<description>Background:
Despite its reported pro-inflammatory activity, cyclooxygenase (COX)-2 has been proposed to play a protective role in asthma. Accordingly, COX-2 might be down-regulated in the airway cells of asthmatics. This, together with results of experiments to assess the impact of COX-2 blockade in ovalbumin (OVA)-sensitized mice in vivo, led us to propose a novel experimental approach using house dust mite (HDM)-sensitized mice in which we mimicked altered regulation of COX-2. 
Methods:
Allergic inflammation was induced in BALBc mice by intranasal exposure to HDM for 10 consecutive days. This model reproduces spontaneous exposure to aeroallergens by asthmatic patients. In order to impair, but not fully block, COX-2 production in the airways, some of the animals received an intranasal antisense oligonucleotide. Lung COX-2 expression and activity were measured along with bronchovascular inflammation, airway reactivity, and prostaglandin production. 
Results:
We observed impaired COX-2 mRNA and protein expression in the lung tissue of selective oligonucleotide-treated sensitized mice. This was accompanied by diminished production of mPGE synthase and PGE2 in the airways. In sensitized mice, the oligonucleotide induced increased airway hyperreactivity (AHR) to methacholine, but a substantially reduced bronchovascular inflammation. Finally, mRNA levels of hPGD synthase remained unchanged.
Conclusions:
Intranasal antisense therapy against COX-2 in vivo mimicked the reported impairment of COX-2 regulation in the airway cells of asthmatic patients. This strategy revealed an unexpected novel dual effect: inflammation was improved but AHR worsened. This approach will provide insights into the differential regulation of inflammation and lung function in asthma, and will help identify pharmacological targets within the COX-2/PG system.</description>
			<link>http://respiratory-research.com/content/9/1/72</link>
			
			 	<dc:creator>Rosa Torres, Aida Herrerias, Mariona Serra-Pages, Jordi Roca-Ferrer, Laura Pujols, Alberto Marco, Cesar Picado and Fernando de Mora</dc:creator>
			
			<dc:source>Respiratory Research 2008, 9:72</dc:source>
			<dc:date>2008-11-12</dc:date>
			<dc:identifier>doi:10.1186/1465-9921-9-72</dc:identifier>
			
			
							
					<prism:publicationName>Respiratory Research</prism:publicationName>
					
			
							
					<prism:issn>1465-9921</prism:issn>
					
			
							
					<prism:volume>9</prism:volume>
					
			
							
					<prism:startingPage>72</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-11-12</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://respiratory-research.com/content/9/1/71">
            
            <title>The Raf-1 inhibitor GW5074 and dexamethasone suppress sidestream smoke-induced airway hyperresponsiveness in mice</title>
			<description>Background:
Sidestream smoke is closely associated with airway inflammation and hyperreactivity. The present study was designed to investigate if the Raf-1 inhibitor GW5074 and the anti-inflammatory drug dexamethasone suppress airway hyperreactivity in a mouse model of sidestream smoke exposure. 
Methods:
Mice were repeatedly exposed to smoke from four cigarettes each day for four weeks. After the first week of the smoke exposure, the mice received either dexamethasone intraperitoneally every other day or GW5074 intraperitoneally every day for three weeks. The tone of the tracheal ring segments was recorded with a myograph system and concentration-response curves were obtained by cumulative administration of agonists. Histopathology was examined by light microscopy.
Results:
Four weeks of exposure to cigarette smoke significantly increased the mouse airway contractile response to carbachol, endothelin-1 and potassium. Intraperitoneal administration of GW5074 or dexamethasone significantly suppressed the enhanced airway contractile responses, while airway epithelium-dependent relaxation was not affected. In addition, the smoke-induced infiltration of inflammatory cells and mucous gland hypertrophy were attenuated by the administration of GW5074 or dexamethasone. 
Conclusion:
Sidestream smoke induces airway contractile hyperresponsiveness. Inhibition of Raf-1 activity and airway inflammation suppresses smoking-associated airway hyperresponsiveness.</description>
			<link>http://respiratory-research.com/content/9/1/71</link>
			
			 	<dc:creator>Ying YL Lei, Yong-Xiao YXC Cao, Cang-Bao CBX Xu and Yaping YPZ Zhang</dc:creator>
			
			<dc:source>Respiratory Research 2008, 9:71</dc:source>
			<dc:date>2008-11-03</dc:date>
			<dc:identifier>doi:10.1186/1465-9921-9-71</dc:identifier>
			
			
							
					<prism:publicationName>Respiratory Research</prism:publicationName>
					
			
							
					<prism:issn>1465-9921</prism:issn>
					
			
							
					<prism:volume>9</prism:volume>
					
			
							
					<prism:startingPage>71</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-11-03</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://respiratory-research.com/content/9/1/70">
            
            <title>Abnormal spatial diffusion of Ca2+ in F508del-CFTR airway epithelial cells</title>
			<description>Background:
In airway epithelial cells, calcium mobilization can be elicited by selective autocrine and/or paracrine activation of apical or basolateral membrane heterotrimeric G protein-coupled receptors linked to phospholipase C (PLC) stimulation, which generates inositol 1,4,5-trisphosphate (IP3) and 1,2-diacylglycerol (DAG) and induces Ca2+ release from endoplasmic reticulum (ER) stores.
Methods:
In the present study, we monitored the cytosolic Ca2+ transients using the UV light photolysis technique to uncage caged Ca2+ or caged IP3 into the cytosol of loaded airway epithelial cells of cystic fibrosis (CF) and non-CF origin. We compared in these cells the types of Ca2+ receptors present in the ER, and measured their Ca2+ dependent activity before and after correction of F508del-CFTR abnormal trafficking either by low temperature or by the pharmacological corrector miglustat (N-butyldeoxynojirimycin).
Results:
We showed reduction of the inositol 1,4,5-trisphosphate receptors (IP3R) dependent-Ca2+ response following both correcting treatments compared to uncorrected cells in such a way that Ca2+ responses (CF+treatment vs wild-type cells) were normalized. This normalization of the Ca2+ rate does not affect the activity of Ca2+-dependent chloride channel in miglustat-treated CF cells. Using two inhibitors of IP3R1, we observed a decrease of the implication of IP3R1 in the Ca2+ response in CF corrected cells. We observed a similar Ca2+ mobilization between CF-KM4 cells and CFTR-cDNA transfected CF cells (CF-KM4-reverted). When we restored the F508del-CFTR trafficking in CFTR-reverted cells, the specific IP3R activity was also reduced to a similar level as in non CF cells. At the structural level, the ER morphology of CF cells was highly condensed around the nucleus while in non CF cells or corrected CF cells the ER was extended at the totality of cell.
Conclusion:
These results suggest reversal of the IP3R dysfunction in F508del-CFTR epithelial cells by correction of the abnormal trafficking of F508del-CFTR in cystic fibrosis cells. Moreover, using CFTR cDNA-transfected CF cells, we demonstrated that abnormal increase of IP3R Ca2+ release in CF human epithelial cells could be the consequence of F508del-CFTR retention in ER compartment.</description>
			<link>http://respiratory-research.com/content/9/1/70</link>
			
			 	<dc:creator>Fabrice Antigny, Caroline Norez, Anne Cantereau, Fr&#233;d&#233;ric Becq and Clarisse Vandebrouck</dc:creator>
			
			<dc:source>Respiratory Research 2008, 9:70</dc:source>
			<dc:date>2008-10-30</dc:date>
			<dc:identifier>doi:10.1186/1465-9921-9-70</dc:identifier>
			
			
							
					<prism:publicationName>Respiratory Research</prism:publicationName>
					
			
							
					<prism:issn>1465-9921</prism:issn>
					
			
							
					<prism:volume>9</prism:volume>
					
			
							
					<prism:startingPage>70</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-10-30</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://respiratory-research.com/content/9/1/69">
            
            <title>Role of pulmonary intravascular macrophages in endotoxin-induced lung inflammation and mortality in a rat model</title>
			<description>Background:
Bile-duct ligated (BDL) rats recruit pulmonary intravascular macrophages (PIMs) and are highly susceptible to endotoxin-induced mortality. The mechanisms of this enhanced susceptibility and mortality in BDL rats, which are used as a model of hepato-pulmonary syndrome, remain unknown. We tested a hypothesis that recruited PIMs promote endotoxin-induced mortality in a rat model.
Methods:
Rats were subjected to BDL to induce PIM recruitment followed by treatment with gadolinium chloride (GC) to deplete PIMs. Normal and BDL rats were treated intravenously with E. coli lipopolysaccharide (LPS) with or without GC pre-treatment followed by collection and analyses of lungs for histopathology, electron microscopy and cytokine quantification.
Results:
BDL rats recruited PIMs without any change in the expression of IL-1&#946;, TNF-&#945; and IL-10. GC caused reduction in PIMs at 48 hours post-treatment (P &lt; 0.05). BDL rats treated intravenously with E. coli LPS died within 3 hours of the challenge while the normal LPS-treated rats were euthanized at 6 hours after the LPS treatment. GC treatment of rats 6 hours or 48 hours before LPS challenge resulted in 80% (1/5) and 100% (0/5) survival, respectively, at 6 hours post-LPS treatment. Lungs from BDL+LPS rats showed large areas of perivascular hemorrhages compared to those pre-treated with GC. Concentrations of IL-1&#946;, TNF-&#945; and IL-10 were increased in lungs of BDL+LPS rats compared to BDL rats treated with GC 48 hours but not 6 hours before LPS (P &lt; 0.05).
Conclusion:
We conclude that PIMs increase susceptibility for LPS-induced lung injury and mortality in this model, which is blocked by a reduction in their numbers or their inactivation.</description>
			<link>http://respiratory-research.com/content/9/1/69</link>
			
			 	<dc:creator>Sukhjit S Gill, Sarabjeet S Suri, Kyathanahalli S Janardhan, Sarah Caldwell, Tanya Duke and Baljit Singh</dc:creator>
			
			<dc:source>Respiratory Research 2008, 9:69</dc:source>
			<dc:date>2008-10-24</dc:date>
			<dc:identifier>doi:10.1186/1465-9921-9-69</dc:identifier>
			
			
							
					<prism:publicationName>Respiratory Research</prism:publicationName>
					
			
							
					<prism:issn>1465-9921</prism:issn>
					
			
							
					<prism:volume>9</prism:volume>
					
			
							
					<prism:startingPage>69</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-10-24</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://respiratory-research.com/content/9/1/68">
            
            <title>Membrane diffusion- and capillary blood volume measurements are not useful as screening tools for pulmonary arterial hypertension in systemic sclerosis: a case control study</title>
			<description>Background:
There is no optimal screening tool for the assessment of pulmonary arterial hypertension (PAH) in patients with systemic sclerosis (SSc). A decreasing transfer factor of the lung for CO (TLCO) is associated with the development of PAH in SSc. TLCO can be partitioned into the diffusion of the alveolar capillary membrane (Dm) and the capillary blood volume (Vc). The use of the partitioned diffusion to detect PAH in SSc is not well established yet. This study evaluates whether Dm and Vc could be candidates for further study of the use for screening for PAH in SSc.
Methods:
Eleven SSc patients with PAH (SScPAH+), 13 SSc patients without PAH (SScPAH-) and 10 healthy control subjects were included. Pulmonary function testing took place at diagnosis of PAH. TLCO was partitioned according to Roughton and Forster. As pulmonary fibrosis in SSc influences values of the (partitioned) TLCO, these were adjusted for fibrosis score as assessed on HRCT.
Results:
TLCO as percentage of predicted (%) was lower in SScPAH+ than in SScPAH- (41 &#177; 7% vs. 63 &#177; 12%, p &lt; 0.0001, respectively). Dm% in SScPAH+ was decreased as compared with SScPAH- (22 &#177; 6% vs. 39 &#177; 12%, p &lt; 0.0001, respectively), also after adjustment for total fibrosis score (before adjustment: B = 17.5, 95% CI 9.0&#8211;25.9, p = &lt; 0.0001; after adjustment: B = 14.3, 95% CI 6.0&#8211;21.7, p = 0.008). No difference was found in Vc%. There were no correlations between pulmonary hemodynamic parameters and Dm% in the PAH groups.
Conclusion:
SScPAH+ patients have lower Dm% than SScPAH- patients. There are no correlations between Dm% and hemodynamic parameters of PAH in SScPAH+. These findings do not support further study of the role of partitioning TLCO in the diagnostic work- up for PAH in SSc.</description>
			<link>http://respiratory-research.com/content/9/1/68</link>
			
			 	<dc:creator>Maria J Overbeek, Herman Groepenhoff, Alexandre E Voskuyl, Egbert F Smit, Jochem WL Peeters, Anton Vonk-Noordegraaf, Marieke D Spreeuwenberg, Ben C Dijkmans and Anco Boonstra</dc:creator>
			
			<dc:source>Respiratory Research 2008, 9:68</dc:source>
			<dc:date>2008-10-01</dc:date>
			<dc:identifier>doi:10.1186/1465-9921-9-68</dc:identifier>
			
			
							
					<prism:publicationName>Respiratory Research</prism:publicationName>
					
			
							
					<prism:issn>1465-9921</prism:issn>
					
			
							
					<prism:volume>9</prism:volume>
					
			
							
					<prism:startingPage>68</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-10-01</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://respiratory-research.com/content/9/1/67">
            
            <title>A multivariate analysis of serum nutrient levels and lung function</title>
			<description>Background:
There is mounting evidence that estimates of intakes of a range of dietary nutrients are related to both lung function level and rate of decline, but far less evidence on the relation between lung function and objective measures of serum levels of individual nutrients. The aim of this study was to conduct a comprehensive examination of the independent associations of a wide range of serum markers of nutritional status with lung function, measured as the one-second forced expiratory volume (FEV1).
Methods:
Using data from the Third National Health and Nutrition Examination Survey, a US population-based cross-sectional study, we investigated the relation between 21 serum markers of potentially relevant nutrients and FEV1, with adjustment for potential confounding factors. Systematic approaches were used to guide the analysis.
Results:
In a mutually adjusted model, higher serum levels of antioxidant vitamins (vitamin A, beta-cryptoxanthin, vitamin C, vitamin E), selenium, normalized calcium, chloride, and iron were independently associated with higher levels of FEV1. Higher concentrations of potassium and sodium were associated with lower FEV1.
Conclusion:
Maintaining higher serum concentrations of dietary antioxidant vitamins and selenium is potentially beneficial to lung health. In addition other novel associations found in this study merit further investigation.</description>
			<link>http://respiratory-research.com/content/9/1/67</link>
			
			 	<dc:creator>Tricia M McKeever, Sarah A Lewis, Henriette A Smit, Peter Burney, Patricia A Cassano and John Britton</dc:creator>
			
			<dc:source>Respiratory Research 2008, 9:67</dc:source>
			<dc:date>2008-09-29</dc:date>
			<dc:identifier>doi:10.1186/1465-9921-9-67</dc:identifier>
			
			
							
					<prism:publicationName>Respiratory Research</prism:publicationName>
					
			
							
					<prism:issn>1465-9921</prism:issn>
					
			
							
					<prism:volume>9</prism:volume>
					
			
							
					<prism:startingPage>67</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-09-29</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://respiratory-research.com/content/9/1/66">
            
            <title>NF-kappaB mediates the survival of human bronchial epithelial cells exposed to cigarette smoke extract</title>
			<description>Background:
We have previously reported that low concentrations of cigarette smoke extract induce DNA damage without leading to apoptosis or necrosis in human bronchial epithelial cells (HBECs), and that IL-6/STAT3 signaling contributes to the cell survival. Since NF-&#954;B is also involved in regulating apoptosis and cell survival, the current study was designed to investigate the role of NF-&#954;B in mediating cell survival in response to cigarette smoke exposure in HBECs.
Methods:
Both the pharmacologic inhibitor of NF-&#954;B, curcumin, and RNA interference targeting p65 were used to block NF-&#954;B signaling in HBECs. Apoptosis and cell survival were then assessed by various methods including COMET assay, LIVE/DEAD Cytotoxicity/Viability assay and colony formation assay.
Results:
Cigarette smoke extract (CSE) caused DNA damage and cell cycle arrest in S phase without leading to apoptosis in HBECs as evidenced by TUNEL assay, COMET assay and DNA content assay. CSE stimulated NF-&#954;B -DNA binding activity and up-regulated Bcl-XL protein in HBECs. Inhibition of NF-&#954;B by the pharmacologic inhibitor curcumin (20 &#956;M) or suppression of p65 by siRNA resulted in a significant increase in cell death in response to cigarette smoke exposure. Furthermore, cells lacking p65 were incapable of forming cellular colonies when these cells were exposed to CSE, while they behaved normally in the regular culture medium.
Conclusion:
The current study demonstrates that CSE activates NF-&#954;B and up-regulates Bcl-XL through NF-kB activation in HBECs, and that CSE induces cell death in cells lacking p65. These results suggest that activation of NF-&#954;B regulates cell survival following DNA damage by cigarette smoke in human bronchial epithelial cells.</description>
			<link>http://respiratory-research.com/content/9/1/66</link>
			
			 	<dc:creator>Xiangde Liu, Shinsaku Togo, Mona Al-Mugotir, Huijung Kim, QiuHong Fang, Tetsu Kobayashi, XingQi Wang, Lijun Mao, Peter Bitterman and Stephen Rennard</dc:creator>
			
			<dc:source>Respiratory Research 2008, 9:66</dc:source>
			<dc:date>2008-09-23</dc:date>
			<dc:identifier>doi:10.1186/1465-9921-9-66</dc:identifier>
			
			
							
					<prism:publicationName>Respiratory Research</prism:publicationName>
					
			
							
					<prism:issn>1465-9921</prism:issn>
					
			
							
					<prism:volume>9</prism:volume>
					
			
							
					<prism:startingPage>66</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-09-23</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://respiratory-research.com/content/9/1/65">
            
            <title>Role of viral hemagglutinin glycosylation in anti-influenza activities of recombinant surfactant protein D</title>
			<description>Background:
Surfactant protein D (SP-D) plays an important role in innate defense against influenza A viruses (IAVs) and other pathogens.
Methods:
We tested antiviral activities of recombinant human SP-D against a panel of IAV strains that vary in glycosylation sites on their hemagglutinin (HA). For these experiments a recombinant version of human SP-D of the Met11, Ala160 genotype was used after it was characterized biochemically and structurally.
Results:
Oligosaccharides at amino acid 165 on the HA in the H3N2 subtype and 104 in the H1N1 subtype are absent in collectin-resistant strains developed in vitro and are important for mediating antiviral activity of SP-D; however, other glycans on the HA of these viral subtypes also are involved in inhibition by SP-D. H3N2 strains obtained shortly after introduction into the human population were largely resistant to SP-D, despite having the glycan at 165. H3N2 strains have become steadily more sensitive to SP-D over time in the human population, in association with addition of other glycans to the head region of the HA. In contrast, H1N1 strains were most sensitive in the 1970s&#8211;1980s and more recent strains have become less sensitive, despite retaining the glycan at 104. Two H5N1 strains were also resistant to inhibition by SP-D. By comparing sites of glycan attachment on sensitive vs. resistant strains, specific glycan sites on the head domain of the HA are implicated as important for inhibition by SP-D. Molecular modeling of the glycan attachment sites on HA and the carbohydrate recognition domain of SPD are consistent with these observations.
Conclusion:
Inhibition by SP-D correlates with presence of several glycan attachment sites on the HA. Pandemic and avian strains appear to lack susceptibility to SP-D and this could be a contributory factor to their virulence.</description>
			<link>http://respiratory-research.com/content/9/1/65</link>
			
			 	<dc:creator>Kevan L Hartshorn, Richard Webby, Mitchell R White, Tesfaldet Tecle, Clark Pan, Susan Boucher, Rodney J Moreland, Erika C Crouch and Ronald K Scheule</dc:creator>
			
			<dc:source>Respiratory Research 2008, 9:65</dc:source>
			<dc:date>2008-09-23</dc:date>
			<dc:identifier>doi:10.1186/1465-9921-9-65</dc:identifier>
			
			
							
					<prism:publicationName>Respiratory Research</prism:publicationName>
					
			
							
					<prism:issn>1465-9921</prism:issn>
					
			
							
					<prism:volume>9</prism:volume>
					
			
							
					<prism:startingPage>65</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-09-23</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://respiratory-research.com/content/9/1/64">
            
            <title>Association of mast cells with lung function in chronic obstructive pulmonary disease</title>
			<description>Background:
In asthma, higher chymase positive mast cell (MC-C) numbers are associated with less airway obstruction. In COPD, the distribution of MC-C and tryptase positive mast cells (MC-T) in central and peripheral airways, and their relation with lung function, is unknown. We compared MC-T and MC-C distributions in COPD and controls without airflow limitation, and determined their relation with lung function.
Methods:
Lung tissue sections from 19 COPD patients (median [interquartile range] FEV1% predicted 56 [23&#8211;75]) and 10 controls were stained for tryptase and chymase. Numbers of MC-T and MC-C were determined in different regions of central and peripheral airways and percentage of degranulation was determined.
Results:
COPD patients had lower MC-T numbers in the subepithelial area of central airways than controls. In COPD, MC-T numbers in the airway wall and more specifically in the epithelium and subepithelial area of peripheral airways correlated positively with FEV1/VC (Spearman's rho (rs) 0.47, p = 0.05 and rs 0.48, p = 0.05, respectively); MC-C numbers in airway smooth muscle of peripheral airways correlated positively with FEV1% predicted (rs 0.57, p = 0.02). Both in COPD patients and controls the percentage of degranulated MC-T and MC-C mast cells was higher in peripheral than in central airways (all p &lt; 0.05), but this was not different between the groups.
Conclusion:
More MC-T and MC-C in peripheral airways correlate with better lung function in COPD patients. It is yet to determine whether this reflects a protective association of mast cells with COPD pathogenesis, or that other explanations are to be considered.</description>
			<link>http://respiratory-research.com/content/9/1/64</link>
			
			 	<dc:creator>Margot ME Gosman, Dirkje S Postma, Judith M Vonk, Bea Rutgers, Monique Lodewijk, Mieke Smith, Marjan A Luinge, Nick HT ten Hacken and Wim Timens</dc:creator>
			
			<dc:source>Respiratory Research 2008, 9:64</dc:source>
			<dc:date>2008-09-10</dc:date>
			<dc:identifier>doi:10.1186/1465-9921-9-64</dc:identifier>
			
			
							
					<prism:publicationName>Respiratory Research</prism:publicationName>
					
			
							
					<prism:issn>1465-9921</prism:issn>
					
			
							
					<prism:volume>9</prism:volume>
					
			
							
					<prism:startingPage>64</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-09-10</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
		
    <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
         <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks"/>
	</cc:License>
</rdf:RDF>
